Table 1.
Clinical characteristics of 22 breast cancer patients with paired samples.
| ID | Age | pCR | MPR | Clin ORR | Menopause | ER | PR | Her-2 | Ki-67 | Disease Stage | Mole Type | His Grade | NAC | NAC Cycle | CD3+ | CD8+ | CD8+PD1+ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | 52 | Yes | Yes | CR | No | + | +++ | – | 15% | IIIA | 2 | 2 | EC-T | 4 | 0.172 | 0.014 | 0.0001 |
| P2 | 48 | No | Yes | PR | No | – | ++ | – | 30% | IIIA | 2 | 2 | EDEC | 8 | 0.059 | 0.001 | 0.000 |
| P3 | 44 | No | No | SD | No | ++ | ++ | + | 30% | IIIA | 2 | 2 | DEC | 8 | 0.105 | 0.011 | 0.0001 |
| P4 | 58 | No | No | PR | Yes | +++ | +++ | +++ | 30% | IIIA | 2 | 2 | TEC | 8 | 0.324 | 0.023 | 0.000 |
| P5 | 40 | No | Yes | PR | No | – | – | +++ | 70% | IIIC | 3 | 2 | EC-T | 8 | 0.051 | 0.001 | 0.000 |
| P6 | 23 | No | No | PR | No | – | – | – | 20% | IIIA | 4 | 2 | DAC | 6 | 0.045 | 0.003 | 0.0003 |
| P7 | 57 | No | Yes | PR | Yes | – | – | +++ | 40% | IIIC | 3 | 2 | TEC | 6 | 0.085 | 0.009 | 0.0001 |
| P8 | 48 | Yes | Yes | CR | No | ++ | +++ | +++ | 20% | IIIA | 2 | 2 | DAC | 6 | 0.177 | 0.029 | 0.0004 |
| P9 | 50 | No | Yes | PR | No | – | – | +++ | 40% | IIIA | 3 | 2 | DAC | 8 | 0.024 | 0.000 | 0.000 |
| P10 | 69 | No | No | PR | Yes | – | – | +++ | 30% | IIIC | 3 | 2 | DEC | 4 | 0.031 | 0.0002 | 0.000 |
| P11 | 30 | Yes | Yes | CR | No | +++ | ++ | – | 70% | IIIA | 2 | 2 | TEC | 7 | 0.081 | 0.033 | 0.002 |
| P12 | 62 | No | No | PR | Yes | +++ | – | + | 5% | IIIC | 1 | 2 | TEC | 6 | 0.007 | 0.003 | 0.0001 |
| P13 | 50 | No | No | PR | No | + | – | +++ | 35% | IIB | 2 | 2 | TEC | 3 | 0.042 | 0.059 | 0.019 |
| P14 | 42 | No | No | SD | No | – | – | ++ | 5% | IIIA | 3 | 3 | TEC | 6 | 0.019 | 0.001 | 0.00001 |
| P15 | 28 | No | No | PR | No | ++ | ++ | – | 20% | IIIA | 2 | 3 | DEC | 5 | 0.192 | 0.002 | 0.0003 |
| P16 | 64 | No | No | PR | Yes | – | + | +++ | 20% | IIIC | 2 | 3 | DEC | 6 | 0.023 | 0.014 | 0.0001 |
| P17 | 41 | No | No | PR | No | +++ | ++ | + | 35% | IIIC | 2 | 2 | TEC | 8 | 0.006 | 0.002 | 0.0001 |
| P18 | 58 | No | No | PD | Yes | – | – | +++ | 30% | IIIC | 3 | 2 | HT-EC | 4 | 0.024 | 0.000 | 0.000 |
| P19 | 52 | No | No | PD | Yes | – | – | +++ | 10% | IIB | 3 | 2 | TH-EC | 6 | 0.029 | 0.001 | 0.00001 |
| P20 | 46 | No | No | PR | No | +++ | ++ | – | 30% | IIIC | 2 | 2 | TEC | 6 | 0.023 | 0.001 | 0.00008 |
| P21 | 50 | No | No | PR | No | +++ | ++ | + | 40% | IIIC | 2 | 2 | TEC | 3 | 0.008 | 0.001 | 0.000 |
| P22 | 50 | No | No | SD | Yes | +++ | + | – | 25% | IIIA | 2 | 3 | TEC | 6 | 0.020 | 0.008 | 0.0002 |
pCR, pathological complete remission; MPR, major pathological response; ORR, objective response rate; ER, estrogen receptor; PR, progesterone receptor; NAC, neoadjuvant chemotherapy.